Influence of Morphine and Naloxone on Pain Modulation in Rheumatoid Arthritis, Chronic Fatigue Syndrome/Fibromyalgia, and Controls: A Double-Blind, Randomized, Placebo-Controlled, Cross-Over Study. — CFSMEATLAS
E1 ReplicatedModerate confidencePEM not requiredRCTPeer-reviewedMachine draft
Standard · 3 min
Influence of Morphine and Naloxone on Pain Modulation in Rheumatoid Arthritis, Chronic Fatigue Syndrome/Fibromyalgia, and Controls: A Double-Blind, Randomized, Placebo-Controlled, Cross-Over Study.
Hermans, Linda, Nijs, Jo, Calders, Patrick et al. · Pain practice : the official journal of World Institute of Pain · 2018 · DOI
Quick Summary
This study tested whether morphine and naloxone (a drug that blocks opioid effects) change how pain is processed in people with ME/CFS, fibromyalgia, rheumatoid arthritis, and healthy controls. Researchers measured pain sensitivity and pain relief in response to these medications using pressure tests and ischemic pain. They found that morphine slightly reduced pain sensitivity in patient groups similarly to placebo, but neither morphine nor naloxone significantly changed how the body's natural pain-relief system worked.
Why It Matters
Understanding why standard pain medications like morphine have limited effectiveness in ME/CFS and fibromyalgia is crucial for developing better treatments. This study provides mechanistic evidence that central sensitization in these conditions may not primarily involve opioid system dysfunction, redirecting research toward other pain-processing pathways. These findings may help explain why opioids are often ineffective or poorly tolerated in ME/CFS patients.
Observed Findings
CFS/FM and RA patients had lower pressure pain thresholds and higher temporal summation at baseline compared to controls.
Morphine increased pain pressure thresholds in both patient groups, but this effect was not significantly different from placebo.
Naloxone had no measurable effects on any pain parameter in controls.
Neither morphine nor naloxone influenced temporal summation or conditioned pain modulation in any group.
The opioid system does not appear to be a dominant mechanism in the enhanced bottom-up sensitization (temporal summation) observed in CFS/FM and RA.
The opioid system does not appear to be responsible for the impaired endogenous pain inhibition (CPM) in these patient populations.
Morphine's modest anti-hyperalgesia effects in CFS/FM and RA patients are not specific to the opioid system, as they equal placebo responses.
Central sensitization pain in CFS/FM may require therapeutic approaches targeting mechanisms beyond opioid signaling.
Remaining Questions
What pain-modulation mechanisms are actually impaired in ME/CFS and fibromyalgia if not the opioid system?
What This Study Does Not Prove
This study does not establish that opioids are never useful in ME/CFS or fibromyalgia—only that they do not work through the measured pain modulation mechanisms. The small sample sizes (10 and 11 patients per group) limit generalizability. A single acute dose of morphine may not reflect effects of chronic opioid therapy or long-term pain system changes.
Tags
Symptom:Pain
Method Flag:PEM Not DefinedSmall SampleMixed Cohort
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →